

**HYPERA S.A.***Companhia Aberta*

CNPJ/MF nº. 02.932.074/0001-91

NIRE nº 35.300.353.251

Código CVM nº. 21431

**MATERIAL FACT**

**HYPERA S.A.**, (“Company” or “Hypera Pharma”), pursuant to the provisions of Article 157, § 4, of Law No. 6404, of December 15, 1976, as amended (“Brazilian Corporations Law”), and the article 2 of Instruction of the Brazilian Securities and Exchange Commission (“CVM”) No. 358, of January 3, 2002, as amended, hereby informs that its Board of Directors approved, in a meeting held on the date hereof, a program for repurchase of common shares issued by the Company, without reduction of the capital stock, for maintenance in treasury, later cancellation, prior sale in the market or to be used the program of assignment of shares based on a matching system and the restricted shares’ grant program of the Company, with the following characteristics (“Repurchase Program”), pursuant to CVM Instruction No. 567, of September 17, 2015 and Brazilian Corporations Law:

(a) the maximum repurchase term under the Repurchase Program is up to 18 months, beginning on April 29, 2019 and ending on October 29, 2020.

(b) the total number of shares to be acquired is up to 8,000,000 (eight million) common shares, representing up to 2.00% of the total of 330,590,554 shares issued by the Company on the market on this date, negotiated on *B3 S.A. – Brasil, Bolsa e Balcão* under the “HYPE3” Trading Code.

(c) the repurchase transactions will be carried out at *B3 S.A. – Brasil, Bolsa e Balcão* at market prices, with the intermediation of Credit Suisse (Brasil) S.A. Corretora de Títulos e Valores Mobiliários, Bradesco S.A. CTVM, Itaú Corretora de Valores S.A. and/or XP Investimentos CCTVM S.A

São Paulo, April 26, 2019.

**HYPERA S.A.**

Adalmario Ghovatto Satheler do Couto  
Investor Relations Officer